Latest news with #RomsdalSparebank
Yahoo
26-03-2025
- Business
- Yahoo
European Stocks That May Be Trading Below Estimated Value In March 2025
As European markets show signs of resilience, with the STOXX Europe 600 Index snapping a two-week losing streak amid hopes for increased government spending, investors are cautiously optimistic despite ongoing trade tensions and inflation concerns. In this climate of mixed economic signals and central banks adopting a wait-and-see approach, identifying stocks that may be trading below their estimated value becomes crucial for those looking to capitalize on potential market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Romsdal Sparebank (OB:ROMSB) NOK130.30 NOK257.92 49.5% Vimi Fasteners (BIT:VIM) €0.97 €1.90 49% TTS (Transport Trade Services) (BVB:TTS) RON4.25 RON8.44 49.6% Stratec (XTRA:SBS) €25.90 €50.97 49.2% F-Secure Oyj (HLSE:FSECURE) €1.722 €3.43 49.8% Deutsche Beteiligungs (XTRA:DBAN) €26.50 €52.70 49.7% dormakaba Holding (SWX:DOKA) CHF687.00 CHF1352.81 49.2% Carasent (OM:CARA) SEK20.715 SEK40.72 49.1% Fodelia Oyj (HLSE:FODELIA) €7.10 €13.91 49% Galderma Group (SWX:GALD) CHF95.77 CHF190.18 49.6% Click here to see the full list of 207 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Overview: Ependion AB, with a market cap of SEK3.99 billion, offers digital solutions for secure control, management, visualization, and data communication in industrial applications. Operations: Ependion's revenue is derived from its Westermo segment, contributing SEK1.32 billion, and Beijer Electronics (including Korenix), which adds SEK946.32 million. Estimated Discount To Fair Value: 48% Ependion appears undervalued, trading at SEK 137.2, significantly below its estimated fair value of SEK 263.89. Despite a decline in sales and net income for 2024 compared to the previous year, the company forecasts robust earnings growth of over 24% annually, outpacing the Swedish market's average. Revenue is expected to grow at 9.4% per year. Although return on equity is projected to be modest at 18%, Ependion's cash flow valuation suggests potential investment appeal. Our earnings growth report unveils the potential for significant increases in Ependion's future results. Click to explore a detailed breakdown of our findings in Ependion's balance sheet health report. Overview: Storytel AB (publ) offers streaming services for audiobooks and e-books, with a market capitalization of SEK7.33 billion. Operations: The company's revenue is primarily derived from its streaming services, which account for SEK3.38 billion, and book sales totaling SEK1.13 billion. Estimated Discount To Fair Value: 47.1% Storytel is trading at SEK 95, significantly below its estimated fair value of SEK 179.44, highlighting its undervaluation based on cash flows. The company became profitable this year, reporting a net income of SEK 196.71 million for 2024 compared to a substantial loss the previous year. Earnings are forecast to grow significantly at 38% annually, surpassing the Swedish market's average growth rate. A strategic partnership with Vodafone Turkey may enhance revenue streams in a key market. Upon reviewing our latest growth report, Storytel's projected financial performance appears quite optimistic. Get an in-depth perspective on Storytel's balance sheet by reading our health report here. Overview: Sulzer Ltd is a global company that develops and sells products and services for fluid engineering and chemical processing applications, with a market cap of CHF5.61 billion. Operations: Sulzer Ltd's revenue is primarily derived from its Flow Equipment segment at CHF1.44 billion, followed by Services at CHF1.25 billion, and Chemtech at CHF837.10 million. Estimated Discount To Fair Value: 28.3% Sulzer is trading at CHF 166.2, notably below its estimated fair value of CHF 231.94, indicating significant undervaluation based on cash flows. The company reported a net income increase to CHF 261.9 million for 2024 from CHF 229.1 million the previous year, with earnings growth forecasted at a robust rate of 12.5% annually, outpacing the Swiss market average. Sulzer also proposed raising its dividend from CHF 3.75 to CHF 4.25 per share for the year 2024. Insights from our recent growth report point to a promising forecast for Sulzer's business outlook. Dive into the specifics of Sulzer here with our thorough financial health report. Delve into our full catalog of 207 Undervalued European Stocks Based On Cash Flows here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OM:EPEN OM:STORY B and SWX:SUN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
24-03-2025
- Business
- Yahoo
European Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.5%
As European markets navigate a complex landscape marked by hopes of increased government spending and trade-related uncertainties, the pan-European STOXX Europe 600 Index has managed to snap two weeks of losses with a modest gain. Against this backdrop, identifying stocks trading below their intrinsic value can be particularly appealing to investors seeking opportunities in an environment where central banks are balancing growth concerns and inflation risks. Name Current Price Fair Value (Est) Discount (Est) Absolent Air Care Group (OM:ABSO) SEK260.00 SEK511.61 49.2% Romsdal Sparebank (OB:ROMSB) NOK130.30 NOK259.93 49.9% Vimi Fasteners (BIT:VIM) €0.97 €1.91 49.2% CTT Systems (OM:CTT) SEK221.00 SEK440.81 49.9% Comet Holding (SWX:COTN) CHF233.00 CHF464.46 49.8% Net Insight (OM:NETI B) SEK4.82 SEK9.58 49.7% Deutsche Beteiligungs (XTRA:DBAN) €26.55 €53.05 50% dormakaba Holding (SWX:DOKA) CHF681.00 CHF1356.93 49.8% Melhus Sparebank (OB:MELG) NOK167.04 NOK329.29 49.3% Neosperience (BIT:NSP) €0.532 €1.06 49.7% Click here to see the full list of 212 stocks from our Undervalued European Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, furniture markets, and other industries globally with a market cap of €1.05 billion. Operations: The company's revenue segments include €176.10 million from the Americas, €131.53 million from the Asia-Pacific region, and €219.05 million from EMEA (Europe, Middle East, and Africa). Estimated Discount To Fair Value: 25.8% Lectra is trading 25.8% below its estimated fair value of €37.47, making it highly undervalued based on discounted cash flow analysis. Despite a slight decline in net income for 2024, earnings are forecast to grow significantly at 23.1% annually over the next three years, outpacing the French market's growth rate of 13%. Revenue is expected to increase by 6% per year, slightly above the market average. The growth report we've compiled suggests that Lectra's future prospects could be on the up. Dive into the specifics of Lectra here with our thorough financial health report. Overview: MedinCell S.A. is a pharmaceutical company based in France that specializes in developing long-acting injectables across various therapeutic areas, with a market capitalization of €497.23 million. Operations: The company's revenue segment is derived entirely from its pharmaceuticals division, amounting to €13.20 million. Estimated Discount To Fair Value: 47.5% MedinCell is trading 47.5% below its estimated fair value of €28.62, indicating it is significantly undervalued based on discounted cash flow analysis. The company anticipates revenue growth of 68.4% annually, surpassing the French market's growth rate, with profitability expected within three years. Recent strategic developments include a €42.9 million equity offering and a $5 million milestone payment from Teva for olanzapine LAI's clinical trial completion, enhancing its financial position amidst robust growth forecasts. According our earnings growth report, there's an indication that MedinCell might be ready to expand. Click here and access our complete balance sheet health report to understand the dynamics of MedinCell. Overview: Cint Group AB (publ) offers software solutions for digital insights and research technology on a global scale, with a market cap of SEK2.68 billion. Operations: Cint Group AB generates revenue through its Cint Exchange segment, contributing €116.82 million, and Media Measurement segment, which adds €49.37 million. Estimated Discount To Fair Value: 17.1% Cint Group, trading at SEK7.55, is undervalued compared to its fair value estimate of SEK9.11, though not significantly. Despite recent shareholder dilution and a volatile share price, the company is expected to achieve profitability within three years with revenue growth outpacing the Swedish market at 5.5% annually. Recent financial results show improved net income and reduced losses year-over-year, supported by a SEK584 million follow-on equity offering to bolster cash reserves amidst strategic initiatives. In light of our recent growth report, it seems possible that Cint Group's financial performance will exceed current levels. Unlock comprehensive insights into our analysis of Cint Group stock in this financial health report. Delve into our full catalog of 212 Undervalued European Stocks Based On Cash Flows here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:LSS ENXTPA:MEDCL and OM:CINT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
